ResearcherI-Shou UniversityActive in the last 2 years
Kun‐Ming Rau
Matched on ORCID iD 0000-0002-1209-3043; OpenAlex author ID A5112485163. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 17
2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 4
- SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217). Co-author DOI 10.1016/j.ejca.2026.116229↗
- Comment on: Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.1093/bjs/znab055↗
- Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. Co-author DOI 10.1111/cas.14264↗
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
Closest collaborators
The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jen‐Shi Chen · 2 shared papers, 2020–2026 · strength 0.35
- Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗
- Paper Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. DOI 10.1111/cas.14264↗
- Li‐Tzong Chen · 2 shared papers, 2020–2026 · strength 0.35
- Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗
- Paper Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. DOI 10.1111/cas.14264↗
- Chung‐Pin Li · 2 shared papers, 2020–2026 · strength 0.35
- Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗
- Paper Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. DOI 10.1111/cas.14264↗
- Yan‐Shen Shan · 2 shared papers, 2020–2026 · strength 0.35
- Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗
- Paper Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. DOI 10.1111/cas.14264↗
- Nai‐Jung Chiang · 1 shared paper, 2026 · strength 0.25
- Yung‐Yeh Su · 1 shared paper, 2026 · strength 0.25
- Tai‐Jan Chiu · 1 shared paper, 2026 · strength 0.25
- Yao‐Yu Hsieh · 1 shared paper, 2026 · strength 0.25
- I‐Wei Ho · 1 shared paper, 2026 · strength 0.25
- Li‐Yuan Bai · 1 shared paper, 2026 · strength 0.25
- Chong‐Chi Chiu · 1 shared paper, 2021 · strength 0.16
- Hye Jin Choi · 1 shared paper, 2020 · strength 0.10
- Bruce Belanger · 1 shared paper, 2020 · strength 0.10
- Do‐Youn Oh · 1 shared paper, 2020 · strength 0.10
- Yung‐Jue Bang · 1 shared paper, 2020 · strength 0.10
- Joon Oh Park · 1 shared paper, 2020 · strength 0.10
- Jun Suk Kim · 1 shared paper, 2020 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.